Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

Cited by papers we hold 6

• Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors · 2024
  No notice
• NK cells are never alone: crosstalk and communication in tumour microenvironments · 2023
  No notice
• Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T · 2023
  No notice
• Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy · 2022
  No notice
• Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects · 2022
  No notice
• Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.